CTOs on the Move


 
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.pronai.com
  • 2150 – 885 West Georgia Street
    Vancouver, BC CAN V6C 3E8
  • Phone: 604.558.6536

Executives

Name Title Contact Details

Similar Companies

Bio-Boiler Systems Inc

Bio-Boiler Systems Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular NeuroImaging

Molecular NeuroImaging is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ST CATHRINE REGINAL HOSP

ST CATHRINE REGINAL HOSP is a Charlestown, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pfizer

97250 Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City.

Innocoll

A specialty pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet important healthcare challenges